Clinical Trials Foundations and Best Practices Training-Day 2
Date: Apr 20, 2026 09:00 AM - 01:00 PM
Fee
$0.00
CE Hours
3.25
CE Units
0.325
Registration closes on Apr 30, 2026 10:00 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Monitoring and safety reporting in Clinical Research
Monitoring and safety reporting in Clinical Research
Objectives
- Describe the purpose and methods of study monitoring, including risk-based monitoring approaches.
- Define adverse events and identify associated reporting requirements in clinical trials.
- Explain safety monitoring and risk management strategies used to protect participants and maintain regulatory compliance.
Speaker(s)/Author(s)
|
Sarah Shami, Pharm.D. |
Activity Number
0010-9999-26-020-L05-P
Date:
04/17/26
Time:
10:25 AM - 11:00 AM
CE Hours
0.50
Mon, Apr 20, 2026
Mon, Apr 20, 2026
Objectives
- Describe the phases of clinical trials (Phase I–IV).
- Identify pharmacists’ roles in managing investigational drugs.
- Explain pharmacists’ role in medication safety, protocol compliance, and adverse event reporting.
Speaker(s)/Author(s)
|
Bisrat Hailemeskel, B.Pharm., MSc, Pharm.D, ABAAHP
|
Activity Number
0010-9999-26-018-L05-P
Date:
04/20/26
Time:
09:05 AM - 09:50 AM
CE Hours
0.75
Objectives
- Describe the principles of quality assurance in clinical trials.
- Explain the importance of compliance with Good Clinical Practice (GCP).
- Outline the difference between the roles of auditing and monitoring in clinical research.
Speaker(s)/Author(s)
|
Salome Weaver, Pharm.D., RPh., Associate Professo |
Activity Number
0010-9999-26-019-L05-P
Date:
04/20/26
Time:
09:50 AM - 10:25 AM
CE Hours
0.50
Objectives
- Describe FDA forms, IRB application, and Laboratory Certificates.
- Explain site selection visits, site initiations visits, and delegation of authority Log.
- Define advertising and recruitment, screening subjects, sponsors monitoring visits, and sponsor closeout visits.
Speaker(s)/Author(s)
|
Sarah Shami, Pharm.D. |
Activity Number
0010-9999-26-021-L05-P
Date:
04/20/26
Time:
11:00 AM - 11:40 AM
CE Hours
0.50
Objectives
- Identify adverse event documentation for serious adverse events.
- Describe investigational product accountability, concomitant medication log, investigational new drug safety reports (INDs), and unanticipated problems involving risks to subjects or others (UPIRTOs).
Speaker(s)/Author(s)
|
Edward Bauer |
Activity Number
0010-9999-26-022-L05-P
Date:
04/20/26
Time:
11:40 AM - 12:30 PM
CE Hours
0.50
Objectives
- Define the role and necessity of CAPA.
- Identify corrective & preventive actions.
- Recognize root cause analysis.
Speaker(s)/Author(s)
|
Sarah Shami, Pharm.D. |
Activity Number
0010-9999-26-022-L05-P
Date:
04/20/26
Time:
12:30 PM - 12:50 PM
CE Hours
0.50

